A Study of Rimegepant for Menstrual Migraine Prevention
This study is looking into how well and how safely rimegepant works to prevent menstrual migraines. If you join, you would receive either rimegepant 75 mg or a placebo (an inactive pill) for 7 days around your period, along with standard acute migraine treatment as needed. The study aims to see if rimegepant can reduce the number of migraine days during your perimenstrual period over 5 months. Women aged 18 to 45 with regular menstrual cycles and a history of menstrual migraines can participate. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 723 participants. It compares rimegepant to a placebo for preventing menstrual migraines.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at 5 months (5 menstrual cycles).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
At a glance
Conditions
Where it's being run
123 sites across 79 statesStudy leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Mean change from the Observation Period in number of migraine days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase5 months (5 menstrual cycles)
Change from Observation Period in the number of migraine days per the 5-day perimenstrual period